6-bromo-5-fluoroisoquinoline | 1432754-56-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 6-bromo-5-fluoroisoquinoline
• 英文别名: 6-Bromo-5-fluoroisoquinoline
• CAS: 1432754-56-7
• 化学式: C₉H₅BrFN
• 分子量: 226.048
• InChiKey: NAUNIYPLNKIBDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-bromo-5-fluoroisoquinoline 在 platinum(IV) oxide 、 tris-(dibenzylideneacetone)dipalladium(0) 、 氢气 、 caesium carbonate 、 二环己胺 、 tri tert-butylphosphoniumtetrafluoroborate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 30.0~100.0 ℃ 、344.75 kPa 条件下， 反应 41.0h， 生成 ethyl 3-(2-(5-(cyclobutylmethyl)-2-fluorophenyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)propanoate
  参考文献：
  名称：

  [EN] SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS
  [FR] COMPOSÉS DE TÉTRAHYDROISOQUINOLINE SUBSTITUÉS UTILES COMME AGONISTES DU GPR120

  摘要：

  本发明涉及一种由公式(I)表示的化合物，以及披露了治疗或预防糖尿病、高脂血症、肥胖、非酒精性脂肪肝炎（NASH）、炎症相关疾病及相关疾病和状况有用的药用可接受盐。这些化合物作为G蛋白偶联受体GPR120的激动剂是有用的。还包含了药物组合物和治疗方法。

  公开号：

  WO2017205193A1

文献信息

• BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：EP3323809A1

  公开（公告）日：2018-05-23

  The present invention provides a bicyclic heterocyclic amide derivative of formula (1) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is -NR3aC(O)-, etc. wherein R3a is hydrogen atom or C1-6 alkyl group; Cy1 is the following group of formula (11), etc.; ring Q2 is optionally-substituted benzene ring, etc.; n and m are indepndently 0, 1 or 2, provided that n and m are not simultaneously 0; X is NR5, etc.; R5 is hydrogen atom, etc.; p is 1, 2, 3, 4 or 5; R4 is, independently when two or more exist, hydrogen atom, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming ability of cancer cells and are useful as an orally-available anti-tumor agent.

  本发明提供了式(1)的双环杂环酰胺衍生物，其中环Q1为任选取代的C6-10芳基等；R1和R2独立地为氢原子等；W1为任选取代的C1-4亚烷基；W2为-NR3aC(O)-等，其中R3a为氢原子或C1-6烷基；Cy1为以下式(11)的基团等；环Q2为任选取代的苯环等。其中，R3a 是氢原子或 C1-6 烷基等；Cy1 是以下式（11）的基团等；环 Q2 是任选取代的苯环等；n 和 m 独立地为 0、1 或 2，条件是 n 和 m 不同时为 0；X 是 NR5 等；R5 是氢原子等；p 是 1、2、3、4 或 5；当存在两个或两个以上时，R4 独立地为氢原子等；以及其药理学上可接受的盐，它们对癌细胞的球形成能力具有强效抑制作用，可用作口服抗肿瘤剂。
• DRUG TARGETING CANCER STEM CELL
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：EP3560494A1

  公开（公告）日：2019-10-30

  The present invention provides an anti-tumor agent comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein ring Q1 is optionally-substituted C6-10 aryl, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is C1-4 alkylene which may be optionally substituted with 1 to 3 fluorine atoms or C3-7 cycloalkyl; W2 is -NR4aC(O)-, etc. wherein R4a is hydrogen atom or C1-6 alkyl; ring Q2 is optionally-substituted C6-10 aryl, etc., in combination with at least one agent selected from the group consisting of an anti-cancer agent, an anti-diabetic agent, an agent for treating dyslipidemia, an agent for treating multiple sclerosis, a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, an anti-fungal agent, and a pharmaceutically acceptable salt thereof.

  本发明提供了一种抗肿瘤剂，包括式（1）化合物或其药学上可接受的盐，其中环 Q1 是任选取代的 C6-10 芳基等；R1 和 R2 独立地为氢原子等；W1 是可任选被 1 至 3 个氟原子取代的 C1-4 亚烷基或 C3-7 环烷基；W2 是-NR4aC(O)-等，其中 R4a 是氢原子或 C1-6 烷基；环 Q2 是任选取代的 C6-10 芳基等、与至少一种选自抗癌剂、抗糖尿病剂、治疗血脂异常的剂、治疗多发性硬化症的剂、类固醇抗炎剂、非类固醇抗炎剂、抗真菌剂及其药学上可接受的盐组成的组的制剂结合使用。
• Bicyclic heterocyclic amide derivative
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US10294237B2

  公开（公告）日：2019-05-21

  The present invention provides a bicyclic heterocyclic amide derivative of formula (1) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)—, etc. wherein R3a is hydrogen atom or C1-6 alkyl group; Cy1 is the following group of formula (11), etc.; ring Q2 is optionally-substituted benzene ring, etc.; n and m are independently 0, 1 or 2, provided that n and m are not simultaneously 0; X is NR5, etc.; R5 is hydrogen atom, etc.; p is 1, 2, 3, 4 or 5; R4 is, independently when two or more exist, hydrogen atom, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming ability of cancer cells and are useful as an orally-available anti-tumor agent.

  本发明提供了式(1)的双环杂环酰胺衍生物，其中环Q1为任选取代的C6-10芳基等；R1和R2独立地为氢原子等；W1为任选取代的C1-4亚烷基；W2为-NR3aC(O)-等，其中R3a为氢原子或C1-6烷基；Cy1为以下式(11)的基团等；环Q2为任选取代的苯环等。n和m独立地为0、1或2，条件是n和m不同时为0；X为NR5等；R5为氢原子等；p为1、2、3、4或5；当存在两个或两个以上时，R4独立地为氢原子等；及其药理学上可接受的盐，它们对癌细胞的成球能力具有强效抑制作用，可作为口服抗肿瘤剂。
• Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US11161819B2

  公开（公告）日：2021-11-02

  The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

  本发明涉及一种由式 (I) 代表的化合物： 及其药学上可接受的盐，可用于治疗或预防糖尿病、高脂血症、肥胖症、NASH、炎症相关疾病以及相关疾病和病症。这些化合物可作为 G 蛋白偶联受体 GPR120 的激动剂。还包括药物组合物和治疗方法。
• Agent for removing undifferentiated iPS cells
  申请人：Sumitomo Pharma Co., Ltd.

  公开号：US11434472B2

  公开（公告）日：2022-09-06

  The present invention provides a compound of formula (1) or a salt thereof wherein ring Q1 is optionally-substituted C6-10 aryl, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is C1-4 alkylene which may be optionally substituted with 1 to 3 fluorine atoms or C3-7 cycloalkyl; W2 is —NR4aC(O)—, etc. wherein R4a is hydrogen atom or C1-6 alkyl; ring Q2 is optionally-substituted C6-10 aryl, etc., which has an inhibitory effect on the sphere-forming ability of cancer cells and is useful an agent for removing iPS cells.

  本发明提供了式(1)化合物或其盐，其中环Q1为任选取代的C6-10芳基等；R1和R2独立地为氢原子等；W1为C1-4亚烷基，可任选被1至3个氟原子或C3-7环烷基取代；W2为-NR4aC(O)-等，其中R4a为氢原子或C1-6烷基；环Q2为任选取代的C6-10芳基等、其中 R4a 是氢原子或 C1-6 烷基；环 Q2 是任选取代的 C6-10 芳基等。